If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Here's what Canadians need to know: Older adults now have access to two approved vaccines, called Arexvy and Abrysvo.